• NEWS . 15 Jun 2020
  • Lower adherence to antiplatelet therapy linked to smoking status and pre-existing CV disease

  • In patients who have undergone recent percutaneous coronary intervention (PCI), poor adherence to antiplatelet agents can increase the risk of stent thrombosis and death. 

    A group of researchers sought to assess the degree of treatment adherence in stable and unstable patients who underwent PCI with drug-eluting stents. To do this, the 8-item Morisky scale was applied at 30 days and 6 months post-PCI to measure P2Y12 receptor inhibitor adherence. 

    The prospective study was carried out between 2014 and 2018 and included a total of 214 patients (65±12 years, 81% men, 61% acute coronary syndromes). Patients in the clopidogrel group were older than those receiving prasugrel (68±12 vs 59±11 years; p<0.01) or ticagrelor (68±12 vs 62±12 years; p<0.01). Patients with low/moderate adherence at 30 days and 6 months represented 19.8% and 27.5% of the study sample, respectively. Current smokers and those with pre-existing cardiovascular (CV) disease at presentation were associated with lower adherence at 30 days.

    In conclusion, the researchers found substantial rates of moderate and low adherence to P2Y12 receptor inhibitors early after PCI. Smoking status and pre-existing CV disease at presentation appeared to be factors associated with low adherence. These findings highlight the need for monitoring adherence to medical treatment after PCI.

    Morita F, et al. Short- and midterm adherence to platelet P2Y12 receptor inhibitors after percutaneous coronary intervention with drug-eluting stents. J Cardiovasc Pharmacol Ther 2020. doi: 10.1177/1074248420926667. [Epub ahead of print]